
Penumbra, Inc.
PENNYSEHealthcareMedical - Devices
最新資料
US$323.95
−US$1.23 · -0.38%
PEN公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
33
Expensive
動能
42
Neutral
情緒
47
Mixed
風險韌性
86
Low Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- US
- 執行長
- Adam Elsesser
- 上市以來
- 2015年9月18日
- 僱員
- 4,700
市場位置
- 成交量
- 3141
- 0.01× 平均值
- 平均成交量
- 40.46萬
- 日均成交量
- 市值
- 127.6億 USD
- 貝塔
- 0.7
- 市場參考 1
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 121.33億 USD
- EV/EBITDA
- 54.19×
- 盈餘收益率
- 1.47%
- 自由現金流收益率
- 1.45%
獲利能力和效率
- 股東權益報酬率
- 12.45%
- 資產報酬率
- 9.73%
- 投入資本報酬率
- 9.88%
財務健康
- 流動比率
- 6.64×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 14.04億 USD | 11.95億 USD | 10.59億 USD | 8.47億 USD | 7.48億 USD |
| 銷貨成本 | 4.61億 USD | 4.4億 USD | 3.76億 USD | 3.12億 USD | 2.72億 USD |
| 毛利 | 9.42億 USD | 7.55億 USD | 6.83億 USD | 5.35億 USD | 4.75億 USD |
| 研究與開發 | 8976.6萬 USD | 9478.3萬 USD | 8442.3萬 USD | 7940.7萬 USD | 1.05億 USD |
| 銷售、一般及管理費用 | 6.63億 USD | 5.74億 USD | 5.06億 USD | 4.5億 USD | 3.78億 USD |
| 營業費用 | 7.53億 USD | 6.69億 USD | 6.09億 USD | 5.29億 USD | 4.83億 USD |
| 利息收入 | 1629.4萬 USD | 1369萬 USD | 682.5萬 USD | 188.6萬 USD | 287.1萬 USD |
| 利息支出 | 131.1萬 USD | 141.8萬 USD | 173.9萬 USD | 174.9萬 USD | 193.3萬 USD |
| 折舊和攤銷 | 1747.1萬 USD | 2370.2萬 USD | 2725.7萬 USD | 2432.1萬 USD | 1640.8萬 USD |
| 營業利益 | 1.89億 USD | 8622.4萬 USD | 7355.1萬 USD | 608.2萬 USD | −750.1萬 USD |
| 淨利 | 1.78億 USD | 1401.2萬 USD | 9095.4萬 USD | −200.2萬 USD | 528.4萬 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 73%
- 優於預期8次、低於預期3次、符合預期0次
- 平均EPS意外幅度
- +4.52%
- 11 類似報告
- 最新每股收益結果
- 0.88
- 預估1.16 · 低於預期24.14%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
評級分佈
22項評級PEN 訊息
PEN同業公司
繼續GoAI的研究
在 GoAI 中研究PENresearch.disclaimer











